CatalystMarker
← board

TKNO

distress 2/10 · well-funded / low risk
$5.240%today-18% from 52w high
teknova.com158 employeesFounded 1996Hollister, CADrug Manufacturers - Specialty & Generic
Revenue
$11M
Liquidity
$18M
Runway
2.3 yrs
Shares 1y
+0%

Price & events

+57.4% over 6M
$1.99$3.94$5.88Jan 26Apr 26Jul 26965k
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-1.5%
1W
+7.2%
1M
+72.9%
3M
+57.8%
6M
+2.7%
1Y
+108.8%
2Y
-70.7%
5Y
-79.0%
All

Overview

Market Cap
$280.94M
Enterprise Value
$289.80M
Volume
19.89K
52 Week Range
$1.99 – $6.37
Total Shares
53.61M
Float Shares
10.88M
Short %
11.47%
% Held by Insiders
9.32%
% Held by Institutions
84.73%
RVOL
0.10x
Beta
0.63

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 53,614,028 · 0 offerings/1y · 0 PIPEs
  • 2025-07-16EFFECTshelf_effective
  • 2025-07-10S-3shelf_registration
  • 2025-03-048-Kmaterial_agreement
  • 2024-08-30424B3offering
  • 2024-08-29EFFECTshelf_effective
  • 2024-08-23S-1shelf_registration
  • 2024-07-19SC 13Dstrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2024-07-10Stephens & Co.Overweight

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.